Article Per Year (5 Year)
p-Index From 2021 - 2026
0.23
P-Index
This Author published in this journals
All Journal Cermin Dunia Kedokteran
Nanang Miftah
RSUD Ulin, Banjarmasin, Indonesia
Health Professions

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Manfaat Klinis Insulin Glargine U300 - Insulin Basal Generasi Kedua: Analisis Nanang Miftah
Cermin Dunia Kedokteran Vol 51 No 11 (2024): Kedokteran Umum
Publisher : PT Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v51i11.1363

Abstract

Untreated diabetes can lead to complications and increase the risk of death. Many patients with type 2 diabetes will require injectable medication within 5-10 years after diagnosis, following the failure of two or three oral antidiabetic therapies. Adding basal insulin can be well tolerated, more effective with lower risks of hypoglycemia and weight gain compared to other insulin regimens, but it carries a risk of hypoglycemia. Insulin glargine U300, with its special formulation, reduces the risk of hypoglycemia in diabetic patients.
Co-Authors